First-of-its-Kind TriNetra™ Blood Test Developed to Detect Breast Cancer

Datar Cancer Genetics Inc developed first-of-its-kind TriNetra™ blood test for the early detection of breast cancer.

TriNetra™, blood test makes use of exclusive technology to identify Circulating Tumor Cells (CTCs) related to breast cancer. Detection of CTCs is considered to be the most dependable and accurate method for the early detection of cancer. According to the studies, it is believed that TriNetra™ can even detect Stage 0 (DCIS) and Stage 1 cancers with high accuracy.

The test can be performed with five milliliters of blood and applicable for asymptomatic women above the age of 40 years. For the first time, women with age of above 40 can obtain breast cancer-specific blood test with a physician's prescription from the convenience and privacy of their home or office.

More than 25,000 women are affected with breast cancer in U.S. Early detection of the disease is essential for cure, since early-stage cancers can be are easily treated than later-stage cancers and the survival rate is also higher.  

US Food and Drug Administration (FDA) grants Breakthrough Device Designation' for TriNetra™ Early-Stage Breast Cancer Detection Blood Test.